Clinical Research Directory
Browse clinical research sites, groups, and studies.
Real-Time Monitoring of Circulating Tumor DNA and Study of Prognostic Factors in Patients Treated With CAR-T Cells
Sponsor: Centre Henri Becquerel
Summary
The purpose of this study is to demonstrate that it is possible to report in real time (less than 3 weeks) to the hematologist the results of the molecular minimal residual disease (MRD) based on blood circulating tumor DNA (ctDNA) assessment taken approximately 7 days after the reinjection of the CAR-T cells, in order to be able to anticipate a possible progression of the disease and to be able to propose salvage or earlier adjuvant therapy to improve patient prognosis.
Official title: Real-Time Monitoring of Circulating Tumor DNA and Study of Prognostic Factors in Patients Treated With Anti-CD19 CAR-T Cells for Relapsed or Refractory Diffuse Large B-cell Lymphoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2023-01-13
Completion Date
2026-09-08
Last Updated
2026-01-02
Healthy Volunteers
No
Conditions
Interventions
CAR-T cells monitoring
monitoring of circulating DNA by blood sample
Locations (1)
Centre Henri Becquerel
Rouen, France